X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Eli Lilly acquire certain rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease, which includes programs, VERVE-101, targeting PCSK9, ANGPTL3 and an undisclosed liver-mediated, cardiovascular target.
Lead Product(s): VERVE-101
Therapeutic Area: Genetic Disease Product Name: VERVE-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $600.0 million Upfront Cash: $250.0 million
Deal Type: Acquisition October 31, 2023
Details:
BEAM-201 is a quadruplex base-edited, anti-CD7 allogeneic chimeric antigen receptor T cell (CAR-T) under clinical investigation for the treatment of CD7+ relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL).
Lead Product(s): BEAM-201,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: BEAM-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
ESCAPE-1 consists multiplex base edited HSCs including therapeutic edit for SCD at the HGB1/2 gene and an additional edit at CD117. ESCAPE antibodies binds to wild-type CD117 and blocks binding of its ligand.
Lead Product(s): Engineered Stem Cell Antibody Paired Evasion
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
As part of its launch, Orbital and Beam Therapeutics have entered into a license and research collaboration under which Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology.
Lead Product(s): RNA-based Medicine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Orbital Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 07, 2022
Details:
RNA-based medicines represent fast-growing and disruptive class of therapeutics for a breadth of disease areas. First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA.
Lead Product(s): RNA-based Vaccine
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Recipient: Orbital Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Under the agreement, Beam will conduct all research activities through Beam’s proprietary base editing technologies, designed to enable a new class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.
Lead Product(s): Precision Genetic Medicine
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,350.0 million Upfront Cash: $300.0 million
Deal Type: Collaboration January 10, 2022
Details:
BEAM-101 is a patient-specific, autologous HSC investigational therapy, that aims to potentially alleviate the effects of mutations causing sickle cell disease (SCD) or beta-thalassemia by leading to increases in fetal hemoglobin, which inhibits HbS polymerization.
Lead Product(s): BEAM-101
Therapeutic Area: Genetic Disease Product Name: BEAM-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2022
Details:
BEAM-101, an investigational, autologous HSC therapy which incorporates base edits that mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin to potentially alleviate the effects of mutations causing SCD or beta-thalassemia.
Lead Product(s): BEAM-101
Therapeutic Area: Genetic Disease Product Name: BEAM-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
Details:
Collaboration combines Apellis’ expertise in complement with Beam’s proprietary base editing platform. Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Apellis Pharmaceuticals
Deal Size: $75.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration June 30, 2021
Details:
With this Acquisition Beam Therapeutics adds GuideTx’s Proprietary LNP screening technology and lipid library supports expanded targeting of diverse tissues for In vivo delivery of gene editing system to its Pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Guide Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
